Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Anders Ullman Biography and Net Worth

Director of Verona Pharma

Since 2016, he has served as Head of the COPD Centre at Sahlgrenska University Hospital, Sweden. From 2013 to 2014, Dr Ullman was Executive Vice President and Head of Research and Development in the BioScience business unit of Baxter International, a healthcare company that became Baxalta. From 2007 to 2013, Dr Ullman was Executive Vice President, Head of Research and Development at Nycomed Pharma, which was acquired by Takeda Pharmaceutical. Dr Ullman received a MD and a PhD in clinical pharmacology from the University of Gothenburg.

How do I contact Anders Ullman?: The corporate mailing address for Mr. Ullman and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Anders Ullman's contact information.
Has Anders Ullman been buying or selling shares of Verona Pharma?: Anders Ullman has not been actively trading shares of Verona Pharma during the past quarter. Most recently, Anders Ullman sold 12,056 shares of the business's stock in a transaction on Tuesday, May 4th. The shares were sold at an average price of $0.84, for a transaction totalling $10,127.04. Learn More on Anders Ullman's trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 1 times. They purchased a total of 39,360 shares worth more than $188,928.00. In the last year, insiders at the sold shares 13 times. They sold a total of 1,178,192 shares worth more than $5,075,998.08. The most recent insider tranaction occured on November, 11th when CEO David Zaccardelli sold 2,400 shares worth more than $12,000.00. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/11/2024.

Anders Ullman Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/4/2021	Sell	12,056	$0.84	$10,127.04
2/1/2021	Sell	10,800	$0.99	$10,692.00

Anders Ullman Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $38.85

$37.61

$39.33

50 Day Range

MA: $33.12

$27.64

$39.87

2 Week Range

Now: $38.85

$11.39

$40.13

Volume

1,155,655 shs

Average Volume

1,099,138 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42